⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AMGN News
Amgen Inc
Migraine Clinical Trial Pipeline Expands as 30+ Companies Driving Innovation in Oncology Therapeutics Space | DelveInsight
globenewswire.com
LUN
LLY
AMGN
NVS
TEVA
ALLER
BHVN
DRREDDY
ABBV
IMPL
ZSAN
AXSM
AEON
IONS
CHRC
AZN
GSK
WSTN
JobKred Joins Visier's Skills OSI to Bridge APAC Skills Gaps and Align Talent Development with Tangible Business Outcomes
prnewswire.com
AMGN
EBAY
F
PAN
[Latest] Global Terahertz Technology Market Size/Share Worth USD 3335.2 Million by 2034 at a 16.74% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
globenewswire.com
MSFT
GOOG
AMZN
NVDA
INTC
QCOM
TCEHY
BABA
CRNT
ERIC
NOK
CSCO
IBM
HPQ
DELL
ORCL
SAP
ACN
INFY
TCS
WMT
COST
HD
MCD
V
MA
JPM
BAC
WFC
GS
MS
C
AXP
CMCSA
VZ
T
TMUS
S
CHTR
NFLX
DIS
CMG
MDT
ABT
JNJ
PFE
MRK
BMY
GILD
AMGN
LLY
UNH
CVS
ANTM
CI
AET
HCA
BA
GD
LMT
RTX
BAX
ISRG
REGN
GPRO
AAPL
TSLA
F
GM
STLA
RIVN
LCID
NIO
XPEV
LI
AMD
QTRX
ALTR
XLNX
ADI
NXPI
ON
STM
WIPRO
HCLTECH
DXC
NTAP
SNPS
CDNS
MRVL
QORVO
PAWR
ETSY
EBAY
MELI
JD
BBY
LOW
PG
KO
PEP
SBUX
NKE
ADDYY
LULU
PVH
RL
GPS
TJX
MGM
LVS
WYNN
MAR
HLT
IHG
CCL
RCL
NCLH
AAL
DAL
UAL
LUV
EXPE
BKNG
PCLN
AVGO
TXN
MU
WDC
SE
SHOP
PYPL
SQ
CRM
ADBE
GOOGL
Accord Healthcare Announces Launch of Denosumab∇ - Second Biosimilar in Bone Health USA - English USA - English
prnewswire.com
AMGN
Accord Healthcare Announces Launch of Denosumab∇ - Second Biosimilar in Bone Health USA - English USA - English
prnewswire.com
AMGN
Next-Generation Biologics and Biosimilars Market to Hit 251.13 billion Dollars by 2033 - Strategic Revenue Insights (SRI)
prnewswire.com
AMGN
PFE
RHHBY
NVS
MRK
LLY
Chronic Kidney Disease Anemia Market Opportunity Assessment and Forecasts 2024-2034: Drug Costs, Safety Improvements, ESA Alternatives, and Enhanced Clinical Trial Design
globenewswire.com
AMGN
JNJ
GSK
ABBVIE
AKORN
AVROBIO
BAYER
MERCK
COSM
ROCHE
CHMP
SHP
ASTELLAS
Familial Hypercholesterolemia Market Intelligence Report 2025-2035 Featuring Regeneron, Amgen, Esperion, Aegerion, Novartis and Other Key Players - Precision Medicine Fuels Personalized Treatment Approaches
globenewswire.com
REGN
AMGN
ESPR
ARWR
Antitumor ADC Drugs Market Forecast Shows Strong 12.86% CAGR Through 2035
globenewswire.com
PFE
AZN
DSNKY
GILD
IMMU
REGN
BIIB
BMY
MRK
NVS
AMGN
LLY
JNJ
ABBV
BNTX
SEGN
RHHBY
Takeda
IQV
PE
TSLP Inhibitors and TSLP Receptor Antagonists Competitor Analysis Report 2025: Early R&D in Tezspire Biosimilars Also Offers Growth Avenues
globenewswire.com
AMGN